BnJ Biopharma Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Early Stage VC
- Investors
-
5
BnJ Biopharma General Information
Description
Developer of an artificial intelligence-based biotechnology platform designed to accelerate the discovery and development of new drugs. The company leverages AI to pioneer drug development, from designing molecules to conducting in vitro and in vivo tests, driving the future of drug discovery with an integrated approach, enabling medical professionals to enhance the quality of life for patients and to shape a better future.
Contact Information
Website
www.bnjbio.comCorporate Office
- 85, Songdo Gwahak-ro, Yeonsu-gu
- Yonsei University International Campus Memorial Hall 2nd floor, Songdo-dong
- Incheon
- South Korea
Corporate Office
- 85, Songdo Gwahak-ro, Yeonsu-gu
- Yonsei University International Campus Memorial Hall 2nd floor, Songdo-dong
- Incheon
- South Korea
BnJ Biopharma Timeline
BnJ Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 07-Dec-2023 | Completed | Startup | |||
| 2. Accelerator/Incubator | 23-Jul-2023 | Completed | Startup | |||
| 1. Seed Round | 31-May-2022 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BnJ Biopharma Patents
BnJ Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226000-A1 | Compounds with proteolytic activity against kras g12d mutant protein and medical uses thereof | Pending | 23-Apr-2025 | ||
| WO-2026225876-A1 | Crbn protac compounds having egfr mutant protein degradation activity and use thereof | Pending | 23-Apr-2025 | ||
| WO-2026226002-A1 | Crbn protac compounds with egfr mutant proteolytic activity and medical uses thereof | Pending | 23-Apr-2025 | ||
| WO-2026226001-A1 | Vhl protac compounds having egfr mutant protein degradation activity and medical uses thereof | Pending | 23-Apr-2025 |
BnJ Biopharma Signals
BnJ Biopharma Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MUST Accelerator | Accelerator/Incubator | Minority | ||
| The Invention Lab | Accelerator/Incubator | Minority | ||
| Tech Incubator Program for Startup | Accelerator/Incubator | |||
| Bigbang Angels | Venture Capital | Minority | ||
| Innocube | Accelerator/Incubator | Minority |
BnJ Biopharma FAQs
-
When was BnJ Biopharma founded?
BnJ Biopharma was founded in 2021.
-
Where is BnJ Biopharma headquartered?
BnJ Biopharma is headquartered in Incheon, South Korea.
-
What is the size of BnJ Biopharma?
BnJ Biopharma has 16 total employees.
-
What industry is BnJ Biopharma in?
BnJ Biopharma’s primary industry is Drug Discovery.
-
Is BnJ Biopharma a private or public company?
BnJ Biopharma is a Private company.
-
What is BnJ Biopharma’s current revenue?
The current revenue for BnJ Biopharma is .
-
How much funding has BnJ Biopharma raised over time?
BnJ Biopharma has raised $386K.
-
Who are BnJ Biopharma’s investors?
MUST Accelerator, The Invention Lab, Tech Incubator Program for Startup, Bigbang Angels, and Innocube have invested in BnJ Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process